PCSK9 Inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27203103.
- Also identified by DOI 10.1016/j.cell.2016.05.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.
Medical subject headings
- Antibodies, Monoclonal
- Anticholesteremic Agents